Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

0Tip RSCInsights

Authors

Mario Eisenberger•Anne-Claire Hardy-Bessard11 more•Johann Bono

Journal

Journal of Clinical Oncology

Published

August 15, 2017

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Oncology

Medicine

Internal Medicine

Urology

Mitoxantrone

Show all topics

DOI

10.1200/jco.2016.72.1076

License

Unknown License